




The relative strengths and weaknesses of Viracta Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viracta Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 84% points. The greatest weakness of Viracta Therapeutics Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 272%, being 34% points above the market average of 238%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	36,322	Assets	37,240
Cost of Goods Sold	0	Liabilities	9,697
Intangible Assets	0	Expenses	25,875
Liabilities, Current	9,416	Revenues	2,073
Liabilities, Non-Current	281	Stockholders Equity	27,543
Other Assets	915	Net Income	-23,330
Other Compr. Net Income	1.0	Comprehensive Net Income	-23,330
Other Expenses	514	BaseVar	37,679
Other Liabilities	0	ECR before LimitedLiability	156%
Other Net Income	472	Economic Capital Ratio	272%
Other Revenues	2,073		
Property and Equipment	3.0		
Research and Development	15,412		
Selling, General and Administrative Expense	9,949		